Performance Forecast - The company expects a net profit attributable to shareholders of approximately 130 million to 180 million yuan, representing an increase of 144.29% to 238.25% compared to the same period last year, which was 53.2152 million yuan [1] - The net profit after deducting non-recurring gains and losses is expected to be between 121 million and 171 million yuan, an increase of 92.79% to 172.45% compared to last year's 62.764 million yuan [1] Reasons for Performance Change - The significant growth in performance is driven by the company's proactive market engagement, expansion of customer channels, and enhanced refined management, which have strengthened its core competitiveness [1] - The company has optimized its product structure, improved market layout, and strengthened cost control, leading to increased revenue and gross profit in its non-sartan raw materials, intermediates, CDMO business, and formulation business [1] - The company has effectively reduced losses by significantly cutting back on foreign exchange derivative trading [1] Non-Recurring Gains and Losses - The estimated impact of non-recurring gains and losses on the net profit attributable to shareholders is approximately 9 million yuan, primarily from government subsidies [2] Audit Status - The performance forecast has not been audited by an accounting firm, and specific financial data will be disclosed in the company's 2025 semi-annual report [1][2]

Core Viewpoint - Tianyu Co., Ltd. (300702) expects a significant increase in net profit for the first half of 2025, projecting a profit of between 130 million to 180 million yuan, representing a growth of 144.29% to 238.25% compared to the same period last year [1] Financial Performance - The net profit attributable to shareholders is projected to be between 130 million to 180 million yuan, compared to 53.2152 million yuan in the same period last year [1] - The net profit after deducting non-recurring gains and losses is expected to be between 121 million to 171 million yuan, an increase from 62.764 million yuan year-on-year, reflecting a growth of 92.79% to 172.45% [1] Growth Drivers - The company's performance growth is driven by actively seizing market opportunities, expanding customer channels, and enhancing refined management [1] - Measures such as optimizing product structure, improving market layout, and strengthening cost control have effectively increased revenue and gross profit in non-sartans raw materials and intermediates, CDMO business, and formulation business [1]

[2025 Semi-Annual Performance Forecast Overview](index=1&type=section&id=PerformanceForecastOverview) Zhejiang Tianyu Pharmaceutical anticipates significant net profit growth in H1 2025, with preliminary estimates indicating a substantial increase in both attributable and non-recurring net profits [I. Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) Zhejiang Tianyu Pharmaceutical expects net profit attributable to shareholders to increase significantly by 144.29% to 238.25% in H1 2025, with non-recurring net profit growing 92.79% to 172.45%, indicating strong performance 2025 Semi-Annual Performance Forecast | Item | Estimated Profit for Current Period (Million CNY) | Profit in Same Period Last Year (Million CNY) | Year-over-Year Growth Rate | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 130 – 180 | 53.2152 | 144.29% - 238.25% | | Net Profit Excluding Non-Recurring Items | 121 – 171 | 62.764 | 92.79% - 172.45% | [II. Pre-Audit Status of Performance Forecast](index=1&type=section&id=II.%20Pre-Audit%20Status%20of%20Performance%20Forecast) This performance forecast is a preliminary estimate by the company's finance department and has not been audited by an accounting firm - This performance forecast has not been audited by an accounting firm[4](index=4&type=chunk) [Analysis of Performance Change Reasons](index=1&type=section&id=PerformanceChangeAnalysis) The company's strong performance is attributed to strategic market engagement, operational efficiencies, product optimization, and reduced foreign exchange losses, complemented by government subsidies [III. Explanation of Performance Change Reasons](index=1&type=section&id=III.%20Explanation%20of%20Performance%20Change%20Reasons) During the reporting period, significant performance growth was primarily driven by seizing market opportunities, expanding customer channels, strengthening refined management, optimizing product structure, improving market layout, and enhancing cost control, leading to increased main business revenue and gross profit; additionally, a substantial reduction in foreign exchange derivative transactions effectively lowered losses, and non-recurring income from government subsidies was received - The company actively seized market opportunities, continuously expanded customer channels, and strengthened refined management, further enhancing its core competitiveness[5](index=5&type=chunk) - In main business expansion, measures such as optimizing product structure, improving market layout, and strengthening cost control effectively boosted revenue and gross profit growth for the company's non-sartan APIs and intermediates, CDMO, and pharmaceutical preparation businesses[5](index=5&type=chunk) - The company significantly reduced foreign exchange derivative transaction volumes, effectively lowering losses[5](index=5&type=chunk) - During the reporting period, non-recurring gains and losses are expected to impact net profit attributable to listed company shareholders by approximately **9 million CNY**, primarily due to government subsidies[5](index=5&type=chunk) [Risk Warning and Subsequent Disclosure](index=1&type=section&id=RiskWarningAndDisclosure) This preliminary, unaudited performance forecast advises investors to exercise caution, with full financial details to be disclosed in the upcoming 2025 semi-annual report [IV. Other Related Explanations](index=1&type=section&id=IV.%20Other%20Related%20Explanations) This performance forecast is a preliminary estimate by the company's finance department, unaudited by an accounting firm; specific financial data will be detailed in the company's 2025 semi-annual report, and investors are advised to make cautious decisions and be aware of investment risks - This performance forecast is a preliminary estimate by the company's finance department and has not been audited by an accounting firm[6](index=6&type=chunk) - Specific financial data will be detailed in the company's 2025 semi-annual report[6](index=6&type=chunk) - Investors are advised to make cautious decisions and be aware of investment risks[6](index=6&type=chunk)[7](index=7&type=chunk)

证券代码：300702 证券简称：天宇股份 公告编号：2025-044 浙江天宇药业股份有限公司 关于全资子公司原料药通过 CDE 评审的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）全资子公司浙江京圣药业有 限公司（以下简称"京圣药业"）依折麦布原料药于近日通过国家药品监督管理局 药品审评中心（以下简称"CDE"）审评。现将相关情况公告如下： 一、药品基本情况 依折麦布制剂由美国默沙东公司（MerckSharp& Dohme）和先灵葆雅公司共 同研发，在临床上主要用于原发性高胆固醇血症。 公司于 2024 年 3 月向 CDE 递交了依折麦布原料药的药品注册申请并获得 受理。依折麦布原料药现已通过CDE审评，尚须取得浙江省药品监督管理局GMP 符合性检查结果为"符合要求"的公示后，方可在国内上市销售。 三、对公司的影响及风险提示 根据 CDE 网站公示，截至公告日，该原料药除公司外，国内获得 CDE 技术 审评通过的厂家有 15 家。京圣药业依折麦布原料药未完成 GMP ...

证券代码：300702 证券简称：天宇股份 公告编号：2025-043 浙江天宇药业股份有限公司 关于全资子公司药品获得批准的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）全资子公司浙江诺得药业 有限公司（以下简称"诺得药业"）于近日收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的关于瑞舒伐他汀依折麦布片（I）的《药品注册证 书》。现将相关情况公告如下： 一、药品情况 1、药品基本情况 | 药品名称 | 瑞舒伐他汀依折麦布片（I） | | | | --- | --- | --- | --- | | 英文名 | Rosuvastatin Calcium and Ezetimibe Tablets (I) | | | | 剂型 | 片剂 | | | | 规格 | 每片含瑞舒伐他汀钙 10mg（按 | C₂₂H₂₈FN₃O₆S | 计）与依折麦布 10mg | | 是否处方药 | 是 | | | | 申请事项 | 药品注册（境内生产） | | | | 注册分类 | 化 ...

证券代码：300702 证券简称：天宇股份 公告 编号：2025-042 浙江天宇药业股份有限公司 信息披露义务人林洁保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 | | 一、 | | 本次股份质押及解除质押的基本情况 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 是否为 | | | | | | | | | | | 质押 | | 占其所 | 占公司 | | | | | | | | 第一大 | | | | 是否 | 是否 | | | | | 股东 | | 股数 | 持股份 | 总股本 | | | | 质押起始 | 质押到期 | | | 股东及 | | | | 为限 | 补充 | | | 质权 | | 人 | 用途 | | | | | | | | | | 名称 | | （万 | 比例 | 比例 | | | 日 | 日 | | | | 一致行 | | | | 售股 | 质押 | | | | | | 股） | | （%） | （%） | | | | | | | | 动人 | ...

证券代码：300702 证券简称：天宇股份 公告编号：2025-042 | 股东 | 是否为 第一大 | 质押 股数 | 占其所 持股份 | 占公司 总股本 | 是否 | 是否 | 质押起始 | 质押到期 | 质权人 | 用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股东及 | （万 | 比例 | 比例 | 为限 | 补充 | 日 | 日 | | | | | 一致行 动人 | 股） | （%） | （%） | 售股 | 质押 | | | | | | 林洁 | 是 | 1,050 | 8.60 | 3.02 | 否 | 否 | 2025-7-7 | 2026-7-6 | 招商证券 股份有限 | 置换前 期质押 | | | | | | | | | | | 公司 | 借款 | 1、股份质押情况 二、股东股份累计质押的情况 浙江天宇药业股份有限公司 关于控股股东部分股份解除质押和质押的公告 信息披露义务人林洁保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司董事会及全体董事 ...

Core Viewpoint - The announcement of a significant share reduction by a key shareholder, which may signal potential concerns regarding the company's future performance and financial stability [1][5][8] Summary by Relevant Sections Reduction Plan Key Details - The shareholder, Tu Shanzeng, plans to reduce holdings by up to 10.439 million shares, representing 3% of total equity, with a maximum reduction amount exceeding 230 million yuan based on the recent closing price of 22.27 yuan [2][3] - The reduction will occur through two methods: a concentrated auction for up to 1% (3.48 million shares) and a block trade for up to 2% (6.96 million shares), with the concentrated auction likely to have a more immediate impact on market prices [2] Time Window - The reduction period is set from July 18, 2025, to October 15, 2025, strategically avoiding lock-up periods and coinciding with a critical operational phase for the company, which may be interpreted as insiders predicting a peak in stock performance [4] Special Nature and Motivation of the Reduction - Tu Shanzeng, as a key figure and father of the actual controller, holds only 3.01% of shares, and the reduction will nearly clear his holdings to 0.01%, sending a strong signal to the market [5] - The stated reason for the reduction is "personal funding needs," but concerns arise due to the company's previous fundraising efforts and the potential implications for long-term valuation [5] Market Impact and Stock Price Pressure - The concentrated auction portion is expected to directly affect market liquidity, potentially leading to follow-on selling if daily trading volumes are significantly impacted [6] - The emotional impact of a near-complete reduction by a controlling shareholder may overshadow the actual financial implications, raising investor concerns about the company's cash flow and project progress [6] - The failure of the planned convertible bond issuance reflects the company's constrained fundraising capabilities, which may further weaken market confidence and affect future refinancing valuations [6][8] Valuation Anchor Loss - The current stock price is below the adjusted price from a 2020 fundraising round, and the significant reduction by a major shareholder may exert long-term pressure on the stock price [7]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced a share reduction plan by its controlling shareholder and actual controller, Tu Shanzeng, who intends to reduce his holdings in the company within a specified timeframe [1] Group 1: Share Reduction Plan - Tu Shanzeng holds 10,479,056 shares, representing 3.01% of the total share capital, and plans to reduce his holdings by up to 3,479,771 shares (1.00%) through centralized bidding and up to 6,959,543 shares (2.00%) via block trading within three months starting from July 18, 2025 [1] Group 2: Fundraising and Financials - Tianyu Co., Ltd. raised a total of 899,999,995.30 RMB by issuing 11,117,974 shares at 80.95 RMB per share, with a net amount of 894,058,095.09 RMB after deducting related expenses [2] - The company distributed cash dividends of 5 RMB per 10 shares, totaling 96,660,322.00 RMB, and also increased its capital stock by 8 shares for every 10 shares held [3] Group 3: Convertible Bonds - The company planned to issue convertible bonds with a total amount not exceeding 140 million RMB, intended for a project to produce 6 billion solid dosage forms and to supplement working capital [4] - The proposal for issuing convertible bonds automatically expired as of July 3, 2024, after the necessary approvals were obtained [4]

证券代码：300702 证券简称：天宇股份 公告编号：2025-040 浙江天宇药业股份有限公司 关于控股股东、实际控制人之一致行动人减持股份 的预披露公告 信息披露义务人控股股东、实际控制人之一致行动人屠善增保证信息披露 的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 浙江天宇药业股份有限公司（以下简称"公司"）于近日收到控股股东、实 际控制人之一致行动人屠善增先生的《关于公司股份减持计划的告知函》，屠善 增先生持有公司股份 10,479,056 股（占公司总股本的比例为 3.01%），计划在自 本公告披露之日起十五个交易日后的三个月内（即 2025 年 7 月 18 日至 2025 年 10 月 15 日），以集中竞价方式减持公司股份不超过 3,479,771 股（占本公司总 股本比例 1.00%），以大宗交易方式减持公司股份不超过 6,959,543 股（占本公司 总股本比例 2.00%）。现将有关情况公告如下： 二、本次减持计划的主要内容 （一）本次减持计划的具体安排 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 ...